New business for Aperto: The digital agency convinced BERLIN-CHEMIE AG in a pitch for the TheraKey® budget. The online therapy support enhances the communication between doctor and patient and offers doctors, patients and relatives a nationwide unique solution for therapy support for different indications. Together with the healthcare experts from Aperto, the respective TheraKey® portals are now being further developed in terms of technology and content.
Aperto will in future be responsible for the design and technological development of the portal. The focus will be on more interactions and better support in changing behaviour patterns, for example through the use of gamification elements.
The goal of the TheraKey® portals is to provide patients with understandable and product-neutral information and everyday aids. Patients are looking for relevant and reliable advice. The Internet has become the first source of research - but information is often difficult to assess and overwhelming in its diversity.
Since 2016, BERLIN-CHEMIE has been offering the digital accompanying program for eight indication areas to date, including diabetes, hypertension, gout and lipometabolic disorders. The curated programme summarises information in a comprehensible form and provides orientation for patients. The passing on of a code by their attending physician gives them access to the relevant content. Quality and data security are ensured through cooperation with renowned partners such as the Fraunhofer Institute for Digital Media Technology and the Cologne Sports University.
BERLIN-CHEMIE AG is a subsidiary of the MENARINI Group, the leading pharmaceutical company in Italy with more than 17,000 employees worldwide. The MENARINI Group has always pursued two strategic objectives with its research and internationalisation activities and is present in the most important therapeutic areas with its products for cardiology, gastroenterology, pneumology/antibiotics, diabetology and anti-inflammatories/analgesics. With 16 production sites and six research and development centres, the MENARINI Group has a strong market presence throughout Europe, Asia, Africa and Central and South America. MENARINI products are available in more than 130 countries worldwide. Further information is available at http://www.menarini.com and https://www.berlin-chemie.de/